Advanced search
Start date
Betweenand

Development of graphene oxide hybrids as platform for the treatment of non-invasive bladder cancer: interactions of Bacillus Calmette-Gueri immunotherapy, metformin and RNA interference

Grant number: 14/11154-1
Support type:Scholarships in Brazil - Post-Doctorate
Effective date (Start): April 01, 2015
Effective date (End): January 31, 2017
Field of knowledge:Health Sciences - Pharmacy - Pharmaceutical Technology
Cooperation agreement: Coordination of Improvement of Higher Education Personnel (CAPES)
Principal researcher:Wagner José Fávaro
Grantee:Joel Gonçalves de Souza
Home Institution: Instituto de Biologia (IB). Universidade Estadual de Campinas (UNICAMP). Campinas , SP, Brazil

Abstract

The most widely used therapy modality for the treatment of bladder cancer (BC) is based on the intravesical administration of Bacillus Calmette-Gueri (BCG) associated with transurethral resection. The anti-tumor effects of BCG start by triggering a systemic immune response involving both humoral and cellular components through the activation of Toll-like receptors (TLR) agonists, providing anti-tumor and anti-angiogenic activity. Despite the anti-cancer activity of BCG, a significant number of patients undergoing this treatment have shown intolerance, besides potentially fatal complications, such as systemic BCG infection. Furthermore, 50 % of non-muscle invasive BC (BCNMI) tumors have recurrence within 4 years after treatment and 11 % of the cases present invasive phenotype. Metformin is a drug used in the treatment of type II diabetes. Several studies demonstrate that metformin has anti cancer activity involving different mechanisms, among them aspects concerning the cellular metabolism. Besides metformin, after the recent discovery of interference RNA (siRNA), these substances started to be studied by silencing genes associated with cancer. In this project, we aim to develop graphene oxide (GO) hybrids for simultaneous administration of metformin and siRNA for VEGF (vascular endothelial growth factor). Furthermore, we propose the association between GO hybrids containing metformin and siRNA and the conventional therapy with BCG. It is expected that such associations potentiate the anti-cancer activity compared to the administration of metformin and siRNA alone and in relation to the usual therapy with BCG. For that, the GO will be chemically modified for entrapment of those molecules. The hybrids will be characterized by physical and chemical methods such as atomic force microscopy (AFM), infrared absorption spectroscopy (FTIR), determination of zeta potential and particle size. The complexation of siRNA by GO will be evaluated by electrophoresis. The in vitro cell transfection will also be evaluated and the VEGF expression will be quantified by ELISA. Ultimately, the hybrids which provide better physicochemical properties, lower cytotoxicity and higher silencing activity under VEGF production will be investigated in vivo to determine the antitumor activity against BCNMI. (AU)

News published in Agência FAPESP Newsletter about the scholarship:

Scientific publications
(References retrieved automatically from Web of Science and SciELO through information on FAPESP grants and their corresponding numbers as mentioned in the publications by the authors)
DURAN, NELSON; FAVARO, WAGNER J.; SEABRA, AMEDEA B. What do we Really Know about Nanotoxicology of Silver Nanoparticles In vivo? New Aspects, Possible Mechanisms, and Perspectives. CURRENT NANOSCIENCE, v. 17, n. 3, p. 292+, 2021. Web of Science Citations: 0.
FAVARO, WAGNER J.; DE SOUZA, JOEL G.; FERREIRA, LUIZ A. B.; DE JESUS, MARCELO B.; DURAN, MARCELA; BOCKELMANN, PETRA K.; BERNARDES, JULIANA S.; DURAN, NELSON. Hybrid graphene oxide as carrier of doxorubicin: cytotoxicity and preliminary in vivo assays against bladder cancer. ADVANCES IN NATURAL SCIENCES-NANOSCIENCE AND NANOTECHNOLOGY, v. 11, n. 2 JUN 2020. Web of Science Citations: 0.
DURAN, NELSON; FAVARO, WAGNER J.; SCABRA, AMCDCA B. What do we Really Know about Nanotoxicology of Silver Nanoparticles In vivo? New Aspects, Possible Mechanisms, and Perspectives. CURRENT NANOSCIENCE, v. 16, n. 3, p. 292-320, 2020. Web of Science Citations: 0.

Please report errors in scientific publications list by writing to: cdi@fapesp.br.

Filed patent(s) as a result of this research project

Solicitação em análise e dentro do prazo legal de sigilo previsto na legislação BR1020170047245 - Universidade Estadual de Campinas (UNICAMP) . Solicitação em análise e dentro do prazo legal de sigilo previsto na legislação - March 2017, 09